Core Insights - In April 2025, out of 668 comparable QDII funds, 346 funds saw an increase in net value, representing over 50% of the total [1] - Only 2 QDII funds had a growth rate exceeding 10%, with 汇添富香港优势精选混合C and 汇添富香港优势精选混合A achieving returns of 14.70% and 14.65% respectively [2] - A total of 38 QDII funds recorded growth between 5% and 10% [3] - 23 QDII funds experienced a decline of over 10%, primarily in the oil and gas sector, with the largest drop being 16.98% [5] Fund Performance - 汇添富香港优势精选混合A and C have year-to-date returns of 59.43% and 59.19%, respectively, since their inception returns are 8.61% and 2.61% [2] - 富国蓝筹精选股票人民币 fund achieved an April return of 8.20% and a year-to-date return of 28.31%, with an inception return of 146.39% [3] - The top holdings for 汇添富香港优势精选混合 funds include companies like 荣昌生物 and 科伦博泰生 [2] Fund Management - The fund manager for 汇添富香港优势精选混合 funds is 张韡, who has extensive experience in the pharmaceutical sector [2] - 富国蓝筹精选股票人民币 is managed by 张峰 and 宁君, both of whom have significant backgrounds in investment banking and fund management [4] Market Trends - The QDII fund market shows a strong performance in the pharmaceutical and technology sectors, with a focus on innovative drugs and high-barrier medical equipment [2][3] - The decline in certain funds is attributed to volatility in the oil and gas market, indicating sector-specific risks [5]